Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Penpulimab in EGFR-mutated NSCLC
NCT06048315Phase 3Not yet recruiting
- Start
- Sep 2023
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of anlotinib and penpulimab in non-small cell lung cancer (NSCLC). Primary endpoint: Progression Free Survival at 12 months. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
anlotinibpenpulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06048315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048315.